Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV
November 11, 2019 08:35 ET
|
Cocrystal Pharma, Inc.
- New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally...